Trichloroethylene Exposure Linked to Genetic Changes in Patients With Kidney Cancer

Publication
Article
OncologyONCOLOGY Vol 13 No 10
Volume 13
Issue 10

Many patients with kidney cancer who had been exposed to high levels of trichloroethylene have a unique pattern of genetic mutations within their cancerous cells. These findings were reported by Hiltrud Brauch, PhD, of the University of Hamburg,

Many patients with kidney cancer who had been exposed to high levels of trichloroethylene have a unique pattern of genetic mutations within their cancerous cells. These findings were reported by Hiltrud Brauch, PhD, of the University of Hamburg, Germany (currently at the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart), and colleagues, in the May 19, 1999, issue of the Journal of the National Cancer Institute.

The authors studied 44 patients with renal cell carcinoma who had been employed in metal processing factories. At the time of their employment, trichloroethylene was widely used as a degreaser, and minimal precautions were taken to prevent workers from exposure to the solvent. An exposure level was determined for each patient by calculating the duration, frequency, and mode of exposure and by ascertaining the presence of any symptoms. Levels of exposure were classified as high, medium, and low.

Mutations in Tumor-Suppressor Gene

The researchers looked for mutations of the von Hippel-Lindau (VHL) tumor-suppressor gene in the DNA extracted from the normal and cancerous tissues of these 44 patients. Control samples from 107 patients with renal cell carcinoma but without known exposure to trichloroethylene were analyzed, and lymphocyte DNA from the 44 study subjects and 97 healthy subjects was tested as well.

Mutations of the VHL gene were found in 33 (75%) of 44 tumors of the workers who had been exposed to trichloroethylene. Among the patients who exhibited mutations, 15 had experienced a high level of exposure to the solvent and 18, a medium exposure level.

A particular mutational hot spot in the VHL gene was seen in the tumors of many of the exposed workers. This mutation was not seen in the lymphocyte DNA of the 44 workers, in lymphocytes from the 97 control subjects who did not have cancer, or in DNA from the tumors of renal cell carcinoma patients who had not been exposed to trichloroethylene.

The authors note that their findings of unique and frequent VHL gene mutations in the cancer cells of workers exposed to trichloroethylene represent the first molecular evidence of a relationship between exposure to a defined carcinogen, gene damage, and kidney cancer.

Recent Videos
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Related Content